Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Small molecule targeting malaria merozoite surface protein-1 (MSP-1) prevents host invasion of divergent plasmodial species.

Chandramohanadas R, Basappa, Russell B, Liew K, Yau YH, Chong A, Liu M, Gunalan K, Raman R, Renia L, Nosten F, Shochat SG, Dao M, Sasisekharan R, Suresh S, Preiser P.

J Infect Dis. 2014 Nov 15;210(10):1616-26. doi: 10.1093/infdis/jiu296. Epub 2014 May 26.

2.

A comparative study of the genetic diversity of the 42kDa fragment of the merozoite surface protein 1 in Plasmodium falciparum and P. vivax.

Pacheco MA, Poe AC, Collins WE, Lal AA, Tanabe K, Kariuki SK, Udhayakumar V, Escalante AA.

Infect Genet Evol. 2007 Mar;7(2):180-7. Epub 2006 Sep 28.

3.

Molecular and biological aspects of antimalarial resistance in Plasmodium falciparum and Plasmodium vivax.

Bustamante C, Batista CN, Zalis M.

Curr Drug Targets. 2009 Mar;10(3):279-90. Review.

PMID:
19275564
5.

Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum.

Vargas-Serrato E, Barnwell JW, Ingravallo P, Perler FB, Galinski MR.

Mol Biochem Parasitol. 2002 Mar;120(1):41-52.

PMID:
11849704
6.

Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species.

O'Donnell RA, Saul A, Cowman AF, Crabb BS.

Nat Med. 2000 Jan;6(1):91-5.

PMID:
10613831
7.

Proteome analysis reveals a large merozoite surface protein-1 associated complex on the Plasmodium falciparum merozoite surface.

Ranjan R, Chugh M, Kumar S, Singh S, Kanodia S, Hossain MJ, Korde R, Grover A, Dhawan S, Chauhan VS, Reddy VS, Mohmmed A, Malhotra P.

J Proteome Res. 2011 Feb 4;10(2):680-91. doi: 10.1021/pr100875y. Epub 2010 Dec 22.

PMID:
21175202
8.

Use of a colorimetric (DELI) test for the evaluation of chemoresistance of Plasmodium falciparum and Plasmodium vivax to commonly used anti-plasmodial drugs in the Brazilian Amazon.

Pratt-Riccio LR, Chehuan YF, Siqueira MJ, das Graças Alecrim M, Bianco-Junior C, Druilhe P, Brasseur P, de Fátima Ferreira-da-Cruz M, Carvalho LJ, Daniel-Ribeiro CT.

Malar J. 2013 Aug 12;12:281. doi: 10.1186/1475-2875-12-281.

9.

Cloning, overexpression and characterization of soluble 42kDa fragment of merozoite surface protein-1 of Plasmodium vivax.

Sheikh IH, Kaushal DC, Singh V, Kumar N, Chandra D, Kaushal NA.

Protein Expr Purif. 2014 Nov;103:64-74. doi: 10.1016/j.pep.2014.08.015. Epub 2014 Sep 4.

PMID:
25195175
10.

Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil.

Aguiar AC, Pereira DB, Amaral NS, De Marco L, Krettli AU.

Malar J. 2014 Feb 28;13:73. doi: 10.1186/1475-2875-13-73.

11.

Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.

Kaushal DC, Kaushal NA, Narula A, Kumar N, Puri SK, Dutta S, Lanar DE.

Indian J Biochem Biophys. 2007 Dec;44(6):429-36.

PMID:
18320841
12.

Identification of a potent combination of key Plasmodium falciparum merozoite antigens that elicit strain-transcending parasite-neutralizing antibodies.

Pandey AK, Reddy KS, Sahar T, Gupta S, Singh H, Reddy EJ, Asad M, Siddiqui FA, Gupta P, Singh B, More KR, Mohmmed A, Chitnis CE, Chauhan VS, Gaur D.

Infect Immun. 2013 Feb;81(2):441-51. doi: 10.1128/IAI.01107-12. Epub 2012 Nov 26.

13.

Therapeutic Approaches Blocking Glycan Synthesis as Targeting Strategy for Malaria.

Gomes PS, Morrot A.

Curr Clin Pharmacol. 2017;12(1):26-30. doi: 10.2174/1574884711666161220152827.

PMID:
28000556
14.

Binding hot spot for invasion inhibitory molecules on Plasmodium falciparum apical membrane antigen 1.

Harris KS, Casey JL, Coley AM, Masciantonio R, Sabo JK, Keizer DW, Lee EF, McMahon A, Norton RS, Anders RF, Foley M.

Infect Immun. 2005 Oct;73(10):6981-9.

15.

Structural studies on Plasmodium vivax merozoite surface protein-1.

Babon JJ, Morgan WD, Kelly G, Eccleston JF, Feeney J, Holder AA.

Mol Biochem Parasitol. 2007 May;153(1):31-40. Epub 2007 Jan 30.

PMID:
17343930
16.

Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy.

Dent A, Malhotra I, Mungai P, Muchiri E, Crabb BS, Kazura JW, King CL.

J Immunol. 2006 Nov 15;177(10):7139-45.

17.

Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.

Woehlbier U, Epp C, Kauth CW, Lutz R, Long CA, Coulibaly B, Kouyaté B, Arevalo-Herrera M, Herrera S, Bujard H.

Infect Immun. 2006 Feb;74(2):1313-22.

19.

Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax.

Marfurt J, Chalfein F, Prayoga P, Wabiser F, Wirjanata G, Sebayang B, Piera KA, Wittlin S, Haynes RK, Möhrle JJ, Anstey NM, Kenangalem E, Price RN.

Antimicrob Agents Chemother. 2012 Oct;56(10):5258-63. doi: 10.1128/AAC.00283-12. Epub 2012 Jul 30.

20.

Proteomic approaches to studying drug targets and resistance in Plasmodium.

Cooper RA, Carucci DJ.

Curr Drug Targets Infect Disord. 2004 Mar;4(1):41-51. Review.

PMID:
15032633

Supplemental Content

Support Center